1. Academic Validation
  2. Synthesis and evaluation of dibenzothiazepines: a novel class of selective cannabinoid-1 receptor inverse agonists

Synthesis and evaluation of dibenzothiazepines: a novel class of selective cannabinoid-1 receptor inverse agonists

  • J Med Chem. 2009 Apr 9;52(7):1975-82. doi: 10.1021/jm801534c.
Hanna Pettersson 1 Anne Bülow Fredrik Ek Jacob Jensen Lars K Ottesen Alma Fejzic Jian-Nong Ma Andria L Del Tredici Erika A Currier Luis R Gardell Ali Tabatabaei Darren Craig Krista McFarland Thomas R Ott Fabrice Piu Ethan S Burstein Roger Olsson
Affiliations

Affiliation

  • 1 ACADIA Pharmaceuticals AB, Malmo, Sweden.
Abstract

A novel class of CB1 inverse agonists was discovered. To efficiently establish structure-activity relationships (SARs), new synthetic methodologies amenable for parallel synthesis were developed. The compounds were evaluated in a mammalian cell-based functional assay and in radioligand binding assays expressing recombinant human cannabinoid receptors (CB1 and CB2). In general, all of the compounds exhibited high binding selectivity at CB1 vs CB2 and the general SAR revealed a lead compound 11-(4-chlorophenyl)dibenzo[b,f][1,4]thiazepine-8-carboxylic acid butylamide (12e) which showed excellent in vivo activity in pharmacodynamic models related to CB1 receptor activity. The low solubility that hampered the development of 12e was solved leading to a potential preclinical candidate 11-(3-chloro-4-fluorophenyl)dibenzo[b,f][1,4]thiazepine-8-carboxylic acid butylamide (12h).

Figures
Products